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Aim of database: The aim of the database is to monitor and improve the treatment and survival 
of melanoma patients.
Study population: All Danish patients with cutaneous melanoma and in situ melanomas must 
be registered in the Danish Melanoma Database (DMD). In 2014, 2,525 patients with invasive 
melanoma and 780 with in situ tumors were registered. The coverage is currently 93% compared 
with the Danish Pathology Register.
Main variables: The main variables include demographic, clinical, and pathological character-
istics, including Breslow’s tumor thickness, ± ulceration, mitoses, and tumor–node–metastasis 
stage. Information about the date of diagnosis, treatment, type of surgery, including safety 
margins, results of lymphoscintigraphy in patients for whom this was indicated (tumors > T1a), 
results of sentinel node biopsy, pathological evaluation hereof, and follow-up information, 
including recurrence, nature, and treatment hereof is registered. In case of death, the cause and 
date are included. Currently, all data are entered manually; however, data catchment from the 
existing registries is planned to be included shortly.
Descriptive data: The DMD is an old research database, but new as a clinical quality register. 
The coverage is high, and the performance in the five Danish regions is quite similar due to 
strong adherence to guidelines provided by the Danish Melanoma Group. The list of monitored 
indicators is constantly expanding, and annual quality reports are issued. Several important 
scientific studies are based on DMD data.
Conclusion: DMD holds unique detailed information about tumor characteristics, the surgical 
treatment, and follow-up of Danish melanoma patients. Registration and monitoring is currently 
expanding to encompass even more clinical parameters to benefit both patient treatment and 
research.
Keywords: melanoma, malignant melanoma, clinical database, quality database, melanoma 
registry, Denmark
Introduction
The Danish Melanoma Group (DMG), which is part of the Danish Multidisciplinary 
Cancer Groups,1 has since 1985 on a national basis collected detailed clinical, surgical, 
pathological, and follow-up information on Danish patients suffering from cutaneous 
melanoma, including in situ lesions, in the Danish Melanoma Database (DMD). The 
DMG is an organization focusing on improving care for Danish melanoma patients. 
All medical specialists with interest in melanoma treatment are involved, and orga-
nization of the database, supporting research, and developing clinical guidelines are 
important parts of the activity.2 Until 2011, the database was a private initiative, driven 
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by dedicated specialists and without stable funding. In 2011, 
the database was approved as a clinical quality database 
under the support of the Danish Regions’ Clinical Quality 
Program, and the first annual quality report was published 
in 2014 based on 2013 data. Since 2011, data registration 
has been performed online, and data from 2000 and onward 
have been entered in the current version. A revision of the 
registration forms/online modules has just been completed, 
and the nature and number of quality indicators included 
in the annual reports are an evolving process. In previous 
publications, slightly different names for the database have 
been used over the years: DMG Database, Danish Melanoma 
Registry, and now the DMD.
Cutaneous melanoma is a potentially deadly disease, 
generally with a high capacity for metastatic spread. The 
prognosis primarily depends on tumor thickness at the time 
of diagnosis. Ulceration of the epithelium and mitotic activ-
ity within the dermal component of the tumor along with 
spread to the draining sentinel node(s) are the other most 
important negative prognostic variables.3 More than half of 
the tumors currently diagnosed are thin (≤1.00 mm) with a 
very good prognosis.4 Treatment of melanoma is surgical 
with local wide excision to secure safety margins; sentinel 
node staging is performed for tumors with a ≥10% risk of 
(micro)metastases to regional lymph nodes (T1b tumors or 
higher: thickness >1.00 mm or if ulceration or mitotic activ-
ity is present).5 Radical lymph node dissection is generally 
performed in case of spread to the regional lymph nodes. 
Solitary metastases are generally treated surgically; however, 
when this is no longer feasible, systemic treatment is offered.2
Aim of database
The aim of the database is to monitor and thereby improve 
treatment and survival for melanoma patients. More specifi-
cally, the purpose of the DMD is to systematically collect 
key clinical parameters on all incident cases of invasive or 
in situ melanoma in Denmark for health care monitoring, 
quality improvement, and research.
Study population
The study population includes all Danish patients with 
cutaneous melanoma, including in situ lesions. New patients 
are registered at the time of diagnosis; for patients already 
in the database, follow-up information including recurrence 
is recorded, in general until 5 years after initial treatment 
or last recurrence. In case of late recurrence, the registra-
tion is resumed. The incidence of melanoma has increased 
at the rate of 4%–5% per year, and in situ lesions perhaps 
even more; however, the preliminary result for 2015 for the 
first time in the history of the database shows a decrease 
of 4.2% for invasive melanoma, while the in situ lesions 
still increase with 3.6%.6 The 2014 annual report included 
2,525 patients with invasive melanoma and 780 with in situ 
lesions,4 corresponding to a crude incidence of 44.6/100,000 
and 13.8/100,000, respectively, and in the 2013 report, 2,325 
patients had  invasive melanoma and 505 had in situ melano-
mas. The database has included ~30,000 patients since 1985.
Table 1 Main variables included in the DMD
Category Variable
Demographic data Sex
Age at diagnosis
Familial melanoma
Presence of dysplastic/atypical nevi
Clinical tumor data Location of tumor (53 different locations)
Largest diameter of tumor
Specific clinical tumor characteristics
Primary diagnosis Type and date of biopsy
Definitive surgery Date of surgery
Excision margin
Method for closure of defect
± Sentinel node biopsy
Pathology data on the 
primary tumor
Melanoma type
Specific pathological tumor characteristics, 
including presence of ulceration and mitoses
Tumor thickness in mm (two decimals) and 
Clark’s level
± Satellites
± Free resection margins
Uncertain whether malignant or benign tumor
Insufficient material for diagnosis
TNM classification
Data from 
lymphoscintigraphy
Date of examination, technique, information on 
tracer, result
Data from sentinel 
node biopsy
Date of surgery, ± use of patent blue, activity 
and stain in removed nodes, remaining activity 
in region
Recurrence Were metastases detected at the time of 
primary diagnosis with a known primary tumor?
Location of recurrence
Treatment of 
recurrence
Date and nature of operation
Results of lymph node dissection (number of 
nodes with metastases and number of nodes 
removed)
Referral to oncological treatment
Follow-up 
information
Date and status at the time of follow-up (± sign 
of recurrence)
In case of recurrence, who/how suspected/
detected
Information about future plan for follow-up
Off-study information Date of last visit
Date and cause of death if known
± Autopsy performed
Abbreviations: DMD, Danish Melanoma Database; TNM, tumor–node–metastasis.
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Main variables
The main variables are listed in Table 1. The pathologist 
performs the primary entry to the DMD. All relevant tumor 
characteristics are registered. The Department of Plastic 
Surgery is responsible for recording the treatment. Currently, 
physicians in primary health care have removed 38% of 
tumors at the time of referral.4 The following information is 
recorded at the first visit: brief information on the history, 
any familial melanoma, location and clinical description of 
the tumor, and details of the bioptic basis for the diagnosis 
(if the tumor is still present, an excisional biopsy is per-
formed at this stage). Later, data on the definite surgery and 
sentinel node biopsy procedure (if performed) are registered, 
including information on method and results of lymphoscin-
tigraphy. Pathological evaluation of the sentinel node(s) is 
recorded with detailed information about location and size 
of metastases. The tumor–node–metastasis stage is recorded. 
In case of metastases at the time of diagnosis or later, the 
clinical information on nature of and location of metastases 
is recorded, as well as overall information about treatment 
for this. Follow-up information including status at the time 
of follow-up (recurrence free, [sign of] recurrence, etc) is 
entered. The DMD currently does not hold data on outcomes 
of systemic treatment; these are registered in a private onco-
logic research database. Information about adjuvant treatment 
has been added by January 2016. In case of death, the patient 
is registered off study with date and cause of death. All data 
have so far been entered manually; however, considerable 
data catchment from the existing registries (the Danish 
Pathology Register, the Danish Civil Registration System, 
and the National Hospital Discharge Register) is planned to 
commence during 2016.
Data quality
Prior to the online registration, all registration forms were 
entered into a database centrally, and missing variables were 
identified and corrections pursued. After the electronic online 
registration was introduced, lists of missing data have been 
produced on key variables, and this list is still expanding in 
order to include all indicators.
Denmark
0 10 20 30 40 50
%
Indicator 3
60 70 80 90 100
Capital Region of
Denmark
Region Zealand
Region of
Southern Denmark
Central Denmark
Region
North Denmark
Region
Figure 1 Regional performance regarding indicator 3 (excisional margins according to guidelines).
Notes: The blue dots present the result for each region and Denmark as a whole (with 95% confidence limits) for quality indicator 3: the fraction of tumors where excisional 
margins are performed according to the guidelines. The vertical dotted line shows the standard set as an aim of acceptance for the indicator by the DMD steering committee. 
Data from Dansk Melanom Database.4
Abbreviation: DMD, Danish Melanoma Database.
Table 2 Current key indicators for the DMD
Indicator 
number
Proportion with required information 
about
Aim
1 TNM stage >90%
2 Excisional margin for treatment of primary tumor >95%
3 If total excisional margin was performed according 
to guidelines
>90%
4 If sentinel lymph node biopsy was performed in 
tumors ≥T1b
>85%
5 Breslow’s tumor thickness >97%
6 Ulceration of the tumor (±) >97%
7 Dermal mitoses (±) >97%
8 Size and location of metastases within metastatic 
sentinel lymph nodes
>97%
9 Metastases (±) in sentinel lymph nodes >97%
10 At least ten lymph nodes removed at axillary 
dissection (including previous sentinel nodes)
>90%
Abbreviations: DMD, the Danish Melanoma Database; TNM, tumor–node–metastasis.
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In the annual quality reports, performance on selected key 
indicators is presented by region and by department.  Figure 1 
is an example of the small regional variation observed for the 
current key indicators (Table 2). The annual quality results 
give a very strong incitement for improving registration. 
Generally, data about on-study information, clinical stage at 
diagnosis, definite treatment, and the concurrent pathologi-
cal variables are registered in 94.5%–98.7% of the cases.4 
Reporting of recurrence has not yet been included in the 
quality report, but we know that the quality of data on this 
is still suboptimal, however improving over time. No formal 
studies on the exact numbers of missing variables have been 
made. The coverage of all melanomas is now evaluated 
by comparison to the Danish Pathology Register,7 and the 
national coverage is 93%.4 In a recent scientific study on 
the incidence from 1985 to 2012, data from the DMD were 
compared with melanomas registered in the Danish Cancer 
Registry.6 This study revealed that the DMD over the years 
has constantly captured ~80%–90% of cases (Figure 2).6 
The Cancer Registry does not hold detailed information 
about location of tumor, tumor characteristics of prognostic 
significance (thickness, ulceration, mitoses), treatment, recur-
rence, follow-up, and in situ cancers and has no information 
about family history.
Follow-up
Follow-up is primarily clinical and includes examination 
of the operated area and the rest of the patient’s skin and 
thorough palpation of lymph node regions as well as the area 
in between, searching for in-transit metastases (lymphatic 
spread is the most common route for metastases in most 
cases). When internal metastases are suspected, imaging 
(primarily positron emission tomography–computed tomog-
raphy) is applied, and ultrasonography-guided fine needle 
aspiration is the method of choice for diagnosis. The use of 
imaging has increased, but not systematically, in patients with 
intermediate to thick tumors where risk of recurrence is not 
negligible and also without actual suspicion of metastases.
The follow-up program has been revised and fully imple-
mented (by January 2016) toward a more intensive program 
for patients with the poorest prognosis and a less frequent 
follow-up for patients with better prognosis.8 Patients with 
T1a tumors and without highly increased risk of second 
melanomas will not be followed up, except for a visit of 
3 months postoperatively. Patients with tumors of interme-
diate thickness, with a negative sentinel node examination 
(stage IB, IIA), will be followed up clinically as described 
with visits twice annually for 5 years. Patients with thick 
tumors and patients with regional metastases at the time of 
30
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Figure 2 Age-standardized incidence rates from the DMD (full lines) compared with age-standardized incidence rates from the NORDCANa (dotted lines).
Notes: aNORDCAN is a collaboration of the cancer registries in the Nordic countries. Data, which can be accessed online in an open version, are derived from the national 
cancer registries and slightly modified to be comparable. Data from Engholm et al.17
Abbreviations: DMD, the Danish Melanoma Database; py, per year; DMG, Danish Melanoma Group.
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 diagnosis (clinical stages IIB, IIC, III) will be followed up with 
a clinical examination of four times a year for the first 2 years 
and then twice a year for the next 3 years. Positron emission 
tomography–computed tomography will be performed after 
6 months, 12 months, 24 months, and 36 months on a routine 
basis. In all stages, further examinations,  imaging, etc will be 
applied when indicated. Besides status at the time of follow-up 
(recurrence free, [sign of] recurrence, etc), database data about 
follow-up will also include information about who suspected 
the recurrence, how it was diagnosed (clinically, due to symp-
toms, or with use of imaging), and which kind of imaging 
was used. The new follow-up program will be monitored in 
a prospective study. Within the next year, linkage to the Dan-
ish Civil Registry will be implemented to achieve complete 
follow-up for survival on all registered melanoma patients.
Examples of research
Data from the DMD have been used for epidemiological, clini-
cal, genetic, pathological, and molecular studies.6,9–14 The recent 
study on the development in incidence is a good example of 
an epidemiological study with use of the data, and this allows 
for monitoring of the development in incidence and mortality 
(a study in preparation) over time.6 Advanced molecular and 
pathology studies have used detailed information from the DMD 
and provided important new knowledge on tumor profiles and 
pathogenesis.11–14 In Denmark, we have unique possibilities for 
high-quality register-based scientific studies because all inhabit-
ants are assigned a unique personal identification number (civil 
personal registration number). With this number, it is possible to 
link to a number of validated health and administrative registries.
Administrative issues and funding
The Danish Health Authority and the Danish Data Protec-
tion Agency have approved the DMD, and the registration is 
mandatory. The DMD is funded by the Danish Regions15 and 
is administered by the Danish Clinical Registries (RKKP),16 
which is the Danish Regions’ Clinical Quality Program. The 
budget allows for the daily maintenance and administration of 
the database, but not for research. The participating depart-
ments collect and report data as part of the clinical work 
without additional financial support. Budget and other report 
drafting for the Danish Regions is maintained with the help 
from the Registry Support Centre (East) – Clinical Quality 
Improvement & Health Informatics.
Conclusion
The DMD is an old database, but new as a clinical quality 
register under the Danish Regions’ Clinical Quality Program. 
Registration is integrated in the daily clinical activities in pathol-
ogy departments as well as in the plastic surgery and oncology 
departments, when responsible for follow-up. The DMD holds 
unique detailed information about tumor  characteristics, sur-
gical treatment, and follow-up. The production of the annual 
quality reports has clarified the need for revision of the registra-
tion forms/electronic modules to ensure the ability to expand 
the monitoring to encompass even more clinical parameters. 
In this way, also the basis for research in the field is improved.
Acknowledgments
This article was funded by the Program for Clinical Research 
Infrastructure established by the Lundbeck Foundation and 
the Novo Nordisk Foundation and administered by the  Danish 
Regions.
The electronic database is developed and managed by 
Aleksandar Jovanovic of Carma Group ApS, and without 
his steady strive for completeness, the database would not 
be in the current good shape. The DMG includes dedicated 
specialists all collaborating for the benefit of the melanoma 
patients. The DMD is controlled by the Steering Committee, 
which includes the members of the DMG’s Board as well as 
specialists in plastic surgery and pathology from regions, not 
represented in the Board. The annual reports are produced 
by Registry Support Centre (East) – Epidemiology and 
Biostatistics where data managers and epidemiologists in 
collaboration with the DMG present the data.
Disclosure
The DMD cooperates with the medical industry in devel-
opment and research. This includes testing of oncologic 
products, clinical tests, participation in advisory boards, 
meetings, and teaching. There are no financial disclosures 
in relation to this work. The authors report no other conflicts 
of interest in this work.
References
 1. Danish Multidisciplinary Cancer Groups (DMCG.dk) [homepage on 
the Internet]. Available from: www.dmcg.dk. Accessed March 13, 2016.
 2. Danish Melanoma Group [homepage on the Internet]. Available from: 
www.melanoma.dk. Accessed May 2, 2016
 3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 
AJCC melanoma staging and classification. J Clin Oncol. 2009; 
27(36):6199–6206.
 4. Dansk Melanom Database [webpage on the Internet]. National 
Årsrapport 2014. Available from: https://www.sundhed.dk/content/
cms/30/57130_%C3%A5rsrapport_melanomer_2014_endelig.pdf. 
Accessed July 29, 2015.
 5. Chakera AH, Hesse B, Burak Z, et al; European Association of Nuclear 
Medicine-European Organisation for Research. EANM-EORTC general 
recommendations for sentinel node diagnostics in melanoma. Eur J 
Nucl Med Mol Imaging. 2009;36(10):1713–1742.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
30
-M
ar
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2016:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Clinical Epidemiology
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/clinical-epidemiology-journal
Clinical Epidemiology is an international, peer-reviewed, open access, 
online journal focusing on disease and drug epidemiology, identifica-
tion of risk factors and screening procedures to develop optimal pre-
ventative initiatives and programs. Specific topics include: diagnosis, 
prognosis, treatment, screening, prevention, risk factor modification, 
systematic reviews, risk and safety of medical interventions, epidemiol-
ogy and biostatistical methods, and evaluation of guidelines, translational 
medicine, health policies and economic evaluations. The manuscript 
management system is completely online and includes a very quick 
and fair peer-review system, which is all easy to use.
Dovepress
548
Hölmich et al
 6. Helvind NM, Hölmich LR, Smith S, et al. Incidence of in situ and 
invasive melanoma in Denmark from 1985 through 2012 a national data-
base study of 24 059 melanoma cases. JAMA Dermatol. 2015;151(10): 
1087–1095.
 7. Bjerregaard B, Larsen OB. The Danish pathology register. Scand J 
Public Health. 2011;39(7 suppl):72–74.
 8. Sundhedsstyrelsen [The Danish Health Authority] [webpage on the 
Internet]. Opfølgningsprogram for modermærkekræft (melanom) 
[Follow-up program for melanoma patients]. Available from: https://
sundhedsstyrelsen.dk/da/udgivelser/2015/~/media/06A4C4DB820A4
9F19311C5879672BE7D.ashx. Accessed May 2, 2016. Danish.
 9. Chakera AH, Drzewiecki KT, Eigtved A, Juhl BR. Sentinel node biopsy for 
melanoma: a study of 241 patients. Melanoma Res. 2004;14(6):521–526.
 10. Jensen TO, Schmidt H, Møller HJ, et al. Macrophage markers in serum 
and tumor have prognostic impact in American Joint Committee on 
Cancer stage I/II melanoma. J Clin Oncol. 2009;27(20):3330–3337.
 11. Weischer M, Heerfordt IM, Bojesen SE, et al. CHEK2 *1100delC and 
risk of malignant melanoma: Danish and German studies and meta-
analysis. J Invest Dermatol. 2012;132(2):299–303.
 12. Lade-Keller J, Riber-Hansen R, Guldberg P, Schmidt H, Hamilton-Dutoit 
SJ, Steiniche T. E- to N-cadherin switch in melanoma is associated with 
decreased expression of phosphatase and tensin homolog and cancer 
progression. Br J Dermatol. 2013;169(3):618–628.
 13. Antonio N, Bønnelykke-Behrndtz ML, Ward LC, et al. The wound 
inflammatory response exacerbates growth of pre-neoplastic cells and 
progression to cancer. EMBO J. 2015;34(17):2219–2236.
 14. Wadt KA, Aoude LG, Krogh L, et al. Molecular characterization of 
melanoma cases in Denmark suspected of genetic predisposition. PLoS 
One. 2015;10(3):e0122662.
 15. Danish Regions [homepage on the Internet]. Available from: http://
www.regioner.dk. Accessed March 14, 2016.
 16. The Danish Clinical Registries (RKKP) [homepage on the Internet]. 
Available from: http://www.rkkp.dk. Accessed March 14, 2016.
 17. Engholm G, Ferlay J, Christensen N, et al [homepage on the Internet]. 
NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival 
in the Nordic Countries, Version 7.2 (16.12.2015). Association of the 
Nordic Cancer Registries. Danish Cancer Society. Available from: http://
www.ancr.nu. Accessed February 2, 2016.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
30
-M
ar
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
